Dapagliflozin Reduced Proteinuria in Kidney Case Study
A single patient with drug-induced glomerular injury saw protein levels drop after starting this diabetes medication.
Updated on Sept. 21, 2026 in Diabetes
A recently published case report highlighted a patient with type 2 diabetes and chronic kidney disease who experienced significant improvement in proteinuria after beginning dapagliflozin. The finding, documented in an August 31, 2026, report, marks a potential area for future research in managing specific forms of glomerular injury.
Why it matters
Managing persistent proteinuria is critical to slowing the progression of chronic kidney disease and protecting long-term organ function. This case explores whether existing treatments like SGLT2 inhibitors might offer benefits beyond standard diabetes management for patients with complex glomerular damage.
In a single-patient case study, researchers observed a reduction in proteinuria from 3.6 g/g Cr to less than 1.0 g/g Cr following the initiation of dapagliflozin. These results are preliminary and have not been confirmed in broader clinical trials.
The players
Dapagliflozin
An SGLT2 inhibitor medication commonly used to manage blood glucose levels in patients with type 2 diabetes and to reduce cardiovascular and kidney risks.
The details
The patient developed collapsing focal segmental glomerulosclerosis, a condition characterized by damaged filtering units in the kidneys, which was linked to nintedanib treatment. After discontinuing nintedanib and utilizing esaxerenone, dapagliflozin was introduced to target the ongoing proteinuria. The medication works by inhibiting SGLT2 proteins in the kidney, which typically reabsorb glucose, helping to reduce pressure within the delicate structures of the glomeruli.
Timeline
Day 606: Patient developed leg edema and 3+ proteinuria.
Day 753: Esaxerenone treatment was initiated.
Day 844: Dapagliflozin treatment was initiated.
Day 1300: Proteinuria levels declined to less than 1.0 g/g Cr.
August 31, 2026: Case report was published online.
Health Landscape
The standard of care for chronic kidney disease has been significantly updated by the DAPA-CKD trial, which established SGLT2 inhibitors as a foundational treatment to slow disease progression. This case study tests the limits of that paradigm by applying the medication to a rare, collapsing form of glomerular injury.
If you are managing chronic kidney disease or diabetes, it is worth discussing the risks and potential benefits of your current treatment regimen with your doctor. Always consult a specialist before considering changes to medications, as individual responses to therapies for complex conditions vary significantly.
The takeaway
This case illustrates that innovative applications of existing drugs are continuously being explored for complex kidney conditions. Patients should continue to track kidney function metrics like eGFR and proteinuria levels through regular, physician-led monitoring.
Further reading
For more information on managing kidney complications, explore our Diabetes section.
